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Abstract 
Background: Chlamydia trachomatis is one of most commonly diagnosed sexually 
transmitted infections worldwide but reports in the literature of an association 
between genital chlamydia infection and adverse obstetric outcomes are 
inconsistent.  
Methods: A cohort of reproductive-aged women was created by linking Birth 
Registrations and Electoral Roll records for women in Western Australia born from 
1974-1995. This cohort was linked to both chlamydia testing records and the state 
perinatal registry for data on preterm births and other adverse obstetric outcomes. 
Associations between chlamydia testing, test positivity and adverse obstetric 
outcomes were determined using multivariate logistic regression.  
Findings: From 2001 to 2013, there were 101,558 women with a singleton birth of 
which 3921 (3·9%) were classified as having a spontaneous preterm birth, 9762 
(9·6%) a small-for-gestational-age baby and 682 (0·7%) a stillbirth. During their 
pregnancy, 21,267 (20·9%) women had at least one chlamydia test record and 1365 
(6·4%) of those tested were positive. Respective numbers of women tested and 
positive prior to pregnancy were 19,157 (18·9%) and 1595 (8·3%). Among all women 
with a test record, after adjusting for age, ethnicity, maternal smoking and history of 
other infections, there was no significant association between a positive chlamydia 
test and spontaneous preterm birth, small-for-gestational-age or stillbirth (adjusted 
OR 1·08 (95%CI 0·91-1·28), 0·95 (0·85-1·07), and 0·93 (0·61-1·42) respectively).  
Interpretation: A genital chlamydia infection diagnosed and treated either during or 
prior to pregnancy does not substantially increase a woman’s risk of adverse 
obstetric outcomes.  
Funding: Australian National Health and Medical Research Council  
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Introduction 
Worldwide, chlamydia is one of the most common sexually transmissible infections 
(STIs) with an estimated 131 million new cases annually; the majority diagnosed in 
women of childbearing age.1 While genital infections are thought to contribute to the 
incidence of adverse obstetric outcomes such as spontaneous preterm birth and 
stillbirth,2 there are limited data regarding the role of chlamydia infections on these 
outcomes. There are no published randomised controlled trials of the effects of 
chlamydia screening in pregnancy on obstetric outcomes.3 Furthermore, randomised 
placebo-controlled prevention trials of antibiotics (including azithromycin) given 
during the antenatal period to high-risk women have found no effect on the rates of 
preterm birth.4 Findings from observational studies have been inconsistent with 
most,5-15 but not all,16-22 suggesting chlamydia infection increases the risk of preterm 
birth. There is similar discordance in studies examining the effects of chlamydia 
infection on birth weight and stillbirth.9,23  
 
There are many possible explanations for the discrepancy in findings between 
published observational studies. These include studies with small numbers of events 
leading to random error; inconsistency in the type of chlamydia test used (serology, 
culture or nucleic-acid amplification); variations in the outcome definition and 
ascertainment; use of case-control designs where control populations may not be 
well matched; inadequate control of potential confounders including other genital 
tract infections, or other factors known to result in adverse obstetric outcomes such 
as smoking during pregnancy; and the potential for publication bias. In this analysis 
we use a large cohort of women with laboratory chlamydia testing and positivity 
records and reliable ascertainment of outcomes to examine the effects of chlamydia 
infection on the risk of spontaneous preterm birth, and other adverse birth outcomes.  
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Methods 
Study population and linkage 
A cohort comprising women of reproductive age residing in the Australian state of 
Western Australia (WA) was constructed by probabilistically linking two whole-
population administrative datasets; Birth Registrations, which contain a record of all 
children born and registered in WA from 1974 onwards, and the WA Electoral Roll. 
Electoral enrolment is compulsory for Australian citizens with an estimated 92% of 
the eligible population included on the roll in WA.24 Eligible women were all those 
born between 1974 and 1995, derived from Birth Registrations or the 2014 WA 
Electoral Roll.  
This cohort was then linked to four datasets: laboratory testing data, the WA 
Midwives Notification System, the WA Notifiable Infectious Diseases Database, and 
the WA Hospital Morbidity Dataset. The laboratory data included all chlamydia 
nucleic-acid amplification tests (NAAT) conducted between 1st January 2001 and 
31st December 2013 at two large pathology laboratories providing services in the 
state as well as tests for gonorrhoea and trichomonas. Data included the test type, 
the date of test, and test result (positive, negative, or equivocal/undetermined). 
Previous analysis has estimated that these two laboratories cover approximately 
50% of all the chlamydia NAAT conducted in the state.25  
The WA Midwives Notification System is a statutory database which receives 
information from birth attendants about all births attended in WA where the infant has 
a gestational age of 20 weeks or more, a birthweight of 400 grams or more, or if 
gestation is unknown. Information available in this dataset includes details regarding 
the birth such as labour onset, gestational age (based mostly on ultrasound or date 
of last menstrual period), birth weight, infant sex, stillbirth, maternal demographics 
and aspects of antenatal care and obstetric history. The WA Notifiable Infectious 
Diseases Database contains a record of all notifiable conditions reported to the WA 
Department of Health under statute including chlamydia, gonorrhoea, syphilis, and 
viral hepatitis. Data obtained included the condition diagnosed and date of onset or 
diagnosis. The WA Hospital Morbidity Dataset includes a record of all public and 
private hospitalisations in the state. Data include the primary diagnosis (coded 
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according to the International Classification of Diseases), any procedures and 
admission and discharge dates.  
Data linkage was conducted by the WA Data Linkage Branch using probabilistic 
matching of personal identifiers such as name, date of birth, address, and sex. 
Linkage accuracy using this process is high with an error rate estimated at 0.11%.26 
All linkage was conducted independent of the study investigators and only de-
identified data were provided for analysis.  
Outcome definitions 
A woman was categorised as having a spontaneous preterm birth if she had a 
delivery at <37 weeks gestation with spontaneous onset of labour. A small-for-
gestational-age baby was defined if the infant birth weight was less than the 10th 
centile for gestational age by infant sex. Stillbirths (>20 weeks gestational age) were 
identified in the Midwives Notification System.  
Exposure to chlamydia testing and infection 
Women were initially categorised according to their history of chlamydia testing in 
relation to the pregnancy. The date of conception was calculated by subtracting the 
number of weeks gestation from the date of birthing. Women were classified as 
‘tested during pregnancy’ if the women had at least one chlamydia test during the 
pregnancy, ‘tested prior to pregnancy’ if there was no record of a test during 
pregnancy but at least one chlamydia test record dated prior to the pregnancy, and 
‘no test record’ if there was no linked chlamydia test prior to the date of birthing. 
As the risk of adverse outcomes could vary according to when a woman was tested, 
analyses were then conducted to determine associations between chlamydia 
positivity and each of the three outcomes taking test timing into account. Women 
were classified into five categories: tested ‘negative’ during pregnancy, tested 
‘positive’ during pregnancy, tested ‘negative’ prior to pregnancy, tested ‘positive’ 
prior to pregnancy and no test record with priority given to tests that occurred most 
proximal to the date of birthing. A three category analysis was also investigated 
examining the association with chlamydia positivity regardless of the timing of the 
test (during or prior to pregnancy).  
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Validity of chlamydia test result was assessed by comparing those testing positive 
from the pathology data with chlamydia notifications from the WA Notifiable 
Infectious Diseases Database.  
Statistical analyses 
Analyses were restricted to women in the cohort who had a first record of a singleton 
birth (regardless of parity), between 2001 and 2012, in the Midwives Notification 
System, and were resident in WA and aged ≥15 years at the time of giving birth.  
Spontaneous preterm birth versus term birth, small-for-gestational-age versus not, 
and stillbirth versus live birth were examined separately, however outcomes were not 
mutually exclusive (e.g. stillbirths could also be classified as born preterm). Those 
with missing outcome data were excluded from each analysis.  
Multivariate logistic regression was used to determine the associations between 
chlamydia testing and positivity and each of the three outcomes. All regression 
analyses were initially adjusted for maternal age at delivery (in 5 year age groups), 
area of residence (metropolitan, rural and remote, based on a Australian standard 
statistical classification of postal codes), and socio-economic status (in tertiles based 
on the Australian Bureau of Statistics Socio-Economic Indexes for Areas). We then 
adjusted for other covariates based on known predictors of adverse obstetric 
outcomes. These included: ethnicity (Caucasian, Aboriginal, other), smoking during 
pregnancy (yes/no), other infections (hepatitis B/C or syphilis notification prior to the 
delivery date); and based on linked pathology data, gonorrhoea and trichomonas (all 
test negative, ≥1 test positive, no test record). Analyses were further adjusted for 
parity (0, 1+), prior adverse obstetric outcomes (for each outcome we included a 
variable indicating if the woman had an earlier birth record of that outcome), 
hypertensive disease (yes/no), gestational and pre-existing diabetes (yes/no), 
antepartum haemorrhage (yes/no), urinary tract infection (yes/no), and use of 
assisted reproductive technologies (ART) (yes/no). Assessment of ART was based 
on a hospital record in the year prior to conception with a code for procreative 
management or assisted reproductive technologies in the diagnosis or procedure 
fields.  The most parsimonious model was reported in the results.  
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As during the period of observation, chlamydia screening guidelines in Australia 
recommended regular testing for young women and Aboriginal women, and 
chlamydia testing increased substantially after 2005,25 analyses were repeated 
stratified by Aboriginality, age (<25 and ≥25 years), and year of giving birth (≤2005, 
>2005). A sub-analysis was also conducted for preterm birth defined as <34 weeks 
gestation.  
All analyses were performed using SAS software version 9.4 (SAS Institute Inc, 
Cary, North Carolina). This study was approved by the Government of WA 
Department of Health Human Research Ethics Committee (Ref #2012/73) and the 
WA Aboriginal Health Ethics Committee (Ref 470). 
Role of funding source 
The funding source had no role in the study design, analysis, interpretation; nor in 
the report writing and decision to submit for publication 
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Results 
We identified 101,558 women with a first record of a singleton birth between 2001 
and 2012 in the cohort. Of births that could be classified, 3921/101558 (3·9%) had a 
spontaneous preterm birth, 9762/101371 (9·6%) births were small-for-gestational-
age and 682/101,558 (0·7%) were stillbirths.  
Table 1 shows women’s characteristics according to birth outcome. Generally, 
women with each of the adverse obstetric outcomes shared similar characteristics. 
They were younger, had lower socioeconomic status, were less likely to be resident 
in a major city, and less likely to identify as Caucasian than those without the three 
adverse outcomes. They were also more likely to have smoked during the 
pregnancy, and to have been diagnosed with hepatitis C, syphilis, gonorrhoea and 
trichomoniasis during or prior to the pregnancy.  
Among the cohort, 21,267 (20·9%) were tested for chlamydia during their pregnancy 
of whom 1365 (6·4%) were positive with the median first chlamydia test date at 14 
weeks gestation; (IQR 8-23 weeks). Among the 19,157 (18·9%) women who only 
had a chlamydia test record prior to their pregnancy, 1595 (8·3%) had a positive 
result with the majority having their most recent test record over a year prior to 
conception (median 1·7 years; IQR 0·6-3·5). The remaining 61,134 (60%) women 
had no linked record of a chlamydia test prior to their date of delivery. Of women who 
had a positive chlamydia test prior to delivery, 91.7% had a chlamydia notification in 
the WA Notifiable Diseases Database during the corresponding period. Whilst of 
those with only negative tests, and those with no test record, 3.2% and 1.4% 
respectively had a chlamydia notification in the corresponding period.    
Figure 1 shows the association between chlamydia testing (grouping those with both 
positive and negative tests together) and each birth outcome evaluated. Compared 
to women who were tested for chlamydia during their pregnancy, women who only 
had a record of testing prior to their pregnancy were significantly more likely to have 
a spontaneous preterm birth (adjusted odds ratio [aOR] 1·15, 95%CI 1·04-1·27, 
p=0·008). The opposite was observed for small-for-gestational-age, with women 
tested for chlamydia prior to pregnancy significantly less likely to have a small-for-
gestational-age baby than those who were tested during pregnancy (aOR 0·86, 
95%CI 0·81-0·92, p<·0001). Women tested for chlamydia prior to pregnancy were 
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also substantially more likely to have a stillbirth than those tested for chlamydia 
during pregnancy (aOR 1·71, 95%CI 1·35-2·17, p<·0001). For each of the three 
outcomes there was no significant difference in risk between women with no test 
record and women tested for chlamydia during their pregnancy in the fully adjusted 
models.  
Figure 2 shows the association between chlamydia positivity and each adverse 
obstetric outcome. Among women tested for chlamydia during their pregnancy, 864 
(4·5%) who were negative for chlamydia and 81 (6·2%) who were positive for 
chlamydia had a spontaneous preterm birth. For women who only had a chlamydia 
test record prior to their pregnancy, 696 (4·1%) test-negative women and 84 (5·5%) 
test-positive women had a spontaneous preterm birth. In models adjusted for age, 
region of residence and socioeconomic status, the risk of spontaneous preterm birth 
in women testing positive versus negative for chlamydia approached, but did not 
reach statistical significance. However, in the fully-adjusted model, there was no 
significant association between chlamydia positivity and spontaneous preterm birth. 
This was the case for women tested during pregnancy (aOR 1·00, 95%CI 0·79-1·27, 
p=0·99) and remained regardless of the trimester during which testing occurred (first 
trimester aOR 1·13, 95%CI 0·82-1·57, p=0·45; second/third trimester aOR 0·88, 
95%CI 0·62-1·25, p=0·48) and in women tested only prior to their pregnancy (aOR 
1·12, 95%CI 0·89-1·42 p=0·33). The main factors resulting in attenuation of the risks 
included adjustment for ethnicity, age and other infections (Appendix page 1).  
Among women tested during pregnancy, a higher percentage of women with a 
positive chlamydia test had a small-for-gestational-age baby than those who tested 
negative (17·1% vs 12·2%). Respective proportions among women only tested for 
chlamydia prior to their pregnancy were 9·6% vs 8·6%. Similar to results for 
spontaneous preterm birth, after adjustments, there were no significant differences in 
the risk of a small-for-gestational-age baby by chlamydia positivity.  
There were too few stillbirths to investigate the association with chlamydia positivity 
stratified by test timing. Twenty-six (0·9%) women with a positive chlamydia test and 
277 (0·7%) women who were negative for chlamydia had a stillbirth (Figure 2) and 
there was no significant association between chlamydia positivity and stillbirth (aOR 
0·93, 95%CI 0·61-1·42, p=0·74).  
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Analyses stratified by Aboriginality, age group and year of giving birth were 
consistent with the main results for both spontaneous preterm birth and small-for-
gestational-age (Table 2). There was also no significant difference in the risk of 
spontaneous preterm birth at <34 weeks by chlamydia positivity (see Appendix page 
2). 
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Discussion 
This large population-based cohort study analysed more than 20,000 women with 
laboratory chlamydia testing data during pregnancy. With over 900 cases of 
spontaneous preterm birth and over 2500 small-for-gestational-age births, we found 
no increase in the risk of having a spontaneous preterm birth or a small-for-
gestational-age baby among women with a positive chlamydia test. While there were 
fewer cases, we also found no evidence to suggest a relationship of a positive 
chlamydia test and stillbirth.  
There has been one systematic review of 7 observational studies14 and a number of 
other observational studies examining the association between genital chlamydia 
infection and preterm birth with equivocal findings reported across studies. As a body 
of evidence, interpreting these findings collectively is difficult for a number of 
reasons. Firstly there is a lack of consistent outcome definition. Some studies have 
not distinguished spontaneous preterm births from all other preterm 
births5,6,9,12,13,18,19,21-23 and in many high-income countries a substantial proportion of 
preterm births are planned (by labour induction or prelabour caesarean section) to 
manage obstetric conditions such as hypertensive diseases.2 Similarly many studies 
report on low birth weight without taking into account gestational age and therefore 
do not clearly distinguish this outcome from preterm birth.7,8,18,23 Secondly, all of the 
larger reports prior to this one do not have information on those who tested negative 
for chlamydia.13,15,21,23 Thirdly some studies do not consider potential confounders 
such as the presence of other genital infections, maternal smoking and ethnicity, and 
therefore have been unable to account for these factors when quantifying 
associations.8,9,12,22 Lack of consideration of such factors can lead to false positive 
results. For example much chlamydia screening has focussed on young women with 
multiple sexual partners.3 Younger age is strongly associated with spontaneous 
preterm birth15 and young women with multiple sexual partners may be more likely to 
take part in higher risk activities such as smoking in pregnancy that also increase the 
risk of adverse obstetric outcomes; hence studies comparing outcomes in positive 
women to those not tested for chlamydia can be biased. Other differences that may 
also contribute to the variation in findings include differences in study populations 
and timing of testing during the pregnancy and the test type.  
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This study had well-defined and reliably reported outcomes27 based on a statutory 
perinatal birth register. We were able to make comparisons between women who 
tested positive and negative for chlamydia and stratify by timing of tests in relation to 
the pregnancy. We also took into account other important factors such as ethnicity, 
maternal smoking and other infections. Furthermore, the cohort design, with 
ascertainment of outcomes and exposures (chlamydia testing information) from 
independent sources (perinatal register and pathology data respectively), reduced 
the likelihood of biased reporting. On systematic searching of the literature, we 
identified four studies larger than this report to have examined the association 
between chlamydia infection and preterm birth13,21,22 including one from our research 
team.15 However, three lacked information on actual testing for chlamydia (ie. they 
compared those with a positive chlamydia test to the rest of the population 
regardless of whether they had been tested for chlamydia)13,15,21 and one case-
control study assessed chlamydia infection through presence of positive serology 
(IgG) and found no association of chlamydia with preterm birth.22  
Our findings, of no increase in the risk of preterm birth with a genital chlamydia 
infection, are plausible and supported by some other observational studies.11,17,19-22 
The substantial attenuation of the risk of any adverse obstetric outcome (including 
preterm birth) that we found after adjusting for other infections and ethnicity support 
the notion that studies that reported positive associations between chlamydia 
infection and preterm birth may be affected by residual confounding. Further, while 
there are no reported trials of chlamydia screening of women in pregnancy to reduce 
preterm birth,3 placebo-controlled trials of prophylactic antibiotics (including 
azithromycin or erythromycin which are both effective against chlamydia) given to 
women during the antenatal4 and preconception period28 have shown no significant 
reduction in preterm birth rates. These trial findings suggest that chlamydia is not a 
major causative organism in preterm birth.  
We did not have treatment data however, an audit of General Practitioner (GP) 
notified chlamydia cases in Western Australia in 2008 found that 91% were 
prescribed either azithromycin (83%) or doxycycline (9%)29 and thus we assumed 
that the majority of women who tested positive were treated for their chlamydia 
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infection.  Hence our results should be interpreted in this light. That is, the risk of 
spontaneous preterm birth is similar between women who tested negative and those 
who tested positive who were treated. That being said, a significant proportion of the 
chlamydia diagnosed in our cohort is likely to have been detected through 
asymptomatic screening29  and therefore the duration of infection prior to testing and 
treatment could vary substantially. We found that women who were tested for 
chlamydia prior to pregnancy, but not during pregnancy, had a greater risk of 
preterm birth and stillbirth (aOR 1·15 and 1·71 respectively; Figure 1) than women 
who were tested during pregnancy. It is possible that women who were only tested 
prior to pregnancy could have undiagnosed and hence untreated chlamydia, or other 
genital infections, during the pregnancy and that the untreated infection (i.e. longer 
duration) may explain the observed increase in the risk of adverse outcomes. 
Alternate explanations could be that these women were less likely to access 
preventative antenatal care (including chlamydia screening), and it is the reduced 
access to care that accounts for their higher risk.  
Only some observational studies examining the association between chlamydia and 
preterm birth have reported on treatment. Of those reporting or assuming treatment, 
some studies found significant associations between chlamydia infection and 
preterm birth18,23 while others were equivocal.14,19 Of studies documenting that the 
chlamydia infections were untreated5,6,16,17,30  four suggested an increase in risk of 
preterm birth but they were all conducted prior to the year 2000 when nucleic-acid 
testing for chlamydia became widespread. The only study17 that showed no increase 
in risk was also the only one to have been conducted after 2000. Future studies of 
untreated chlamydia infection in pregnancy are unlikely to be ethical however studies 
where routine post-partum testing for chlamydia (regardless of obstetric outcome) is 
conducted may identify potentially untreated infections that had been present during 
pregnancy and assist in establishing whether an untreated infection is itself a risk 
factor for preterm birth.  
While our linked pathology data did not include all tests conducted in the state,25 our 
main comparisons are between women who tested positive for chlamydia and those 
who tested negative. It is conceivable that some women may have been tested at 
more than one laboratory but our data from the two labs show this was minimal with 
no women tested at more than one of the labs during pregnancy and less than 10% 
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tested at more than one of the labs in the three years prior to pregnancy. Other 
caveats on interpreting our findings include the lack of data on NAAT titres that may 
correlate with severity of infection, and clinical information on whether infections 
were symptomatic or not. Therefore we could not investigate whether more severe 
infections themselves are associated with an increased risk of adverse birth 
outcomes.  Nor were we able to examine factors such as effects of host genetic 
susceptibility.   
This is the largest study, in the era of widespread nucleic acid testing, to compare 
the risk of adverse birth outcomes in women with a positive and negative chlamydia 
test. Our results suggest that a chlamydia infection diagnosed and presumably 
treated either during or prior to pregnancy does not increase a woman’s risk of 
spontaneous preterm birth, small-for-gestational-age birth or stillbirth. These findings 
support the continued screening of high risk women during pregnancy for chlamydia 
and they should reassure women who have chlamydia diagnosed during pregnancy 
and treated that there is no increased risk of serious adverse birth outcomes.  
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Table 1 Participant characteristics according to birth outcome in Western Australian women born 1974-1995 
 
  All births Term Preterm Small-for-gestational-age Stillbirth 
    Planned∞ Spontaneous No Yes  
N 
 
101558 94276 3361 3921 91609 9762 682 
% of all births 
 
100.0 92.8 3.3 3.9 90.4 9.6 0.7 
Demographics        
Median age, years 26.8 26.8 26.8 26.2 26.9 26.1 25.7 
 (IQR) (23.0-29.8) (23.0-29.8) (23.0-30.0) (21.7-29.7) (23.1-29.9) (21.7-29.5) (22.2-29.3) 
% lower third socioeconomic status (N) 35.2 (35722) 35.0 (33023) 35.3 (1187) 38.6 (1513) 34.7(31755) 39.8 (3885) 37.6 (256) 
% resident in major city (N) 74.1 (75240) 74.2 (69917) 75.8 (2549) 70.7 (2774) 74.7 (68427) 68.5 (6687) 67.9 (463) 
% Caucasian (N) 83.1 (84385) 83.6 (78785) 78.3 (2630) 75.7 (2970) 84.4 (77288) 71.3 (6962) 74.2 (506) 
% Aboriginal (N) 8.0 (8087) 7.5 (7062) 11.7 (392) 16.1 (633) 7.1 (6493) 15.9 (1556) 15.4 (105) 
% other ethnicity (N) 8.9 (9086) 8.9 (8429) 10.1 (339) 8.1 (318) 8.5 (7828) 12.7 (1244) 10.4 (71) 
Antenatal factors 
        % smoked cigarettes during pregnancy (N) 17.4 (17673) 17.0 (16024) 19.8 (664) 25.1 (985) 16.0 (14617) 30.8 (3010) 25.7 (175) 
% nulliparous (N) 59.3 (60184) 59.3 (55941) 57.2 (1922) 59.2 (2321) 59.2 (54189) 60.3 (5889) 58.9 (402) 
% ART¥ prior to conception (N) 1.3 (1282) 1.2 (1136) 2.4 (82) 1.6 (64) 1.3 (1179) 1.0 (98) 1.3 (16) 
Infections†        
% hepatitis C (N) 0.7 (754) 0.7 (658) 1.1 (37) 1.5 (59) 0.7 (626) 1.3 (125) 1.2 (*) 
% hepatitis B (N) 0.4 (370) 0.4 (342) 0.4 (12) 0.4 (16) 0.3 (301) 0.7 (67) 0.3 (*) 
% syphilis (N) 0.1(122) 0.1 (107) 0.2 (*) 0.2(*) 0.1 (90) 0.3 (32) 0.4 (*) 
% gonorrhoea (N) 1.2(1200) 1.1 (1032) 2.1(72) 2.5(96) 1.0(901) 3.0(293) 1.4 (17) 
% trichomoniasis (N) 0.3 (348) 0.3 (294) 0.8 (26) 0.7 (28) 0.3 (261) 0.9 (85) 0.3 (*) 
*small cell numbers suppressed, ∞including labour inductions and prelabour caesarean sections, †diagnosed during or prior to pregnancy 
¥Hospital record of access to assisted reproductive technology in year prior to conception (see methods) 
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Table 2 Association between chlamydia positivity and adverse obstetric outcomes by Aboriginality, age, and year of 
giving birth 
    Minimally adjusted* Fully adjusted+ Heterogeneity 
  
N n OR (95%CI) OR (95%CI) P value  
Spontaneous preterm birth Chlamydia      
Aboriginality       
Non-Aboriginal 
 
negative  31535 1191 1.00 1.00 0.74 
positive  1939 83 1.11 (0.89-1.40) 1.09 (0.87-1.38)  
Aboriginal 
 
negative  4558 369 1.00 1.00  
positive  899 82 1.10 (0.86-1.42) 1.10 (0.85-1.42)  
Age group (years)       
<25 negative  14212 689 1.00 1.00 0.71 
 positive  1881 121 1.31 (1.07-1.60) 1.12 (0.92-1.37)  
≥25 negative  21881 871 1.00 1.00  
  positive  957 44 1.17 (0.85-1.59) 1.09 (0.80-1.49)  
Year of giving birth       
2001-2005 negative  5827 307 1.00 1.00 0.45 
 positive  533 38 1.24 (0.87-1.76) 1.06 (0.74-1.51)  
2006-2012 negative  30266 1253 1.00 1.00  
 positive  2305 127 1.22 (1.00-1.47) 1.10 (0.90-1.33)  
Small-for-gestational-age       
Aboriginality       
Non-Aboriginal 
 
negative  32614 2938 1.00 1.00  
positive  2000 203 1.09 (0.94-1.27) 1.04 (0.90-1.21) 0.23 
Aboriginal 
 
negative  4785 995 1.00 1.00  
positive  943 180 0.87 (0.73-1.05) 0.83 (0.69-1.00)  
Age group (years)       
<25 negative  14706 1874 1.00 1. 00  
 positive  1956 285 1.12 (0.98-1.29) 0.94 (0.81-1.08) 0.73 
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≥25 negative  22693 2059 1.00 1.00  
 positive  987 98 1.09 (0.88-1.35) 0.98 (0.79-1.22)  
Year of giving birth       
2001-2005 negative  6047 817 1.00 1.00 0.76 
 positive  550 93 1.12 (0.89-1.42) 0.93 (0.73-1.19)  
2006-2012 negative  31352 3116 1.00 1.00  
 positive  2393 290 1.12 (0.98-1.27) 0.96 (0.84-1.10)  
21 
 
Figure 1: Association between chlamydia testing history and adverse obstetric outcomes 
 
Minimally adjusted model adjusted for age, area of residence, and socioeconomic status  
Fully adjusted model adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity 
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Figure 2: Association between chlamydia positivity and adverse obstetric outcomes 
 
Women with no test record were included in the analysis but data not shown 
Minimally adjusted model adjusted for age, area of residence, and socioeconomic status  
Fully adjusted model adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity 
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Appendix 
Table 1 Association between chlamydia positivity (combining tested during and prior to pregnancy) and adverse obstetric 
outcomes 
 a b c d e f g h 
 OR (95%CI ) OR (95%CI ) OR (95%CI ) OR (95%CI ) OR (95%CI ) OR (95%CI ) OR (95%CI ) OR (95%CI ) 
Spontaneous preterm birth  
 negative  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 positive  1.37 (1.16-1.61) 1.24 (1.05-1.47) 1.23 (1.04-1.45) 1.22 (1.04-1.45) 1.20 (1.01-1.41) 1.15 (0.97-1.36) 1.08 (0.91-1.28) 1.08 (0.91-1.28) 
         
Small for gestational age  
negative  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
positive  1.27 (1.14-1.43) 1.14 (1.02-1.28) 1.12 (1.00-1.25) 1.11 (0.99-1.25) 1.06 (0.95-1.19) 1.00 (0.89-1.13) 0.95 (0.85-1.07) 0.95 (0.85-1.07) 
         
Stillbirth  
negative 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
positive 1.19 (0.80-1.79) 1.08 (0.72-1.62) 1.06 (0.70-1.59) 1.05 (0.70-1.59) 1.03 (0.69-1.54) 0.98 (0.65-1.49) 0.93 (0.61-1.42) 0.93 (0.62-1.42) 
Models in bold type were reported in Figure 2 in main report 
Model a: Unadjusted 
Model b: Adjusted for age  
Model c: Adjusted for age, and area of residence 
Model d: Adjusted for age, area of residence, and socioeconomic status 
Model e: Adjusted for age, area of residence, socioeconomic status, and smoked during pregnancy 
Model f: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, and other infections listed in table 1  
Model g: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity 
Model h: Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1, ethnicity and use of 
assisted reproductive technologies.  
  
24 
 
Table 2 Association between chlamydia testing history and spontaneous preterm birth at ≥34 weeks and <34 weeks 
    Minimally adjusted* Fully adjusted+ 
  Pop Case OR (95%CI ) OR (95%CI ) 
≥34 weeks Chlamydia     
Tested during pregnancy negative  18927 607 1.00 1.00 
positive  1289 62 1.34 (1.02-1.76) 1.17 (0.89-1.54) 
 
 
    
Tested prior to pregnancy negative  16705 492 1.00 1.00 
positive  1501 55 0.99 (0.88-1.13) 0.99 (0.77-1.26) 
      
Combined Tested during and prior to pregnancy 
 
 
Tested  at any time 
negative  35632 1099 1.00 1.00 
positive  2790 117 1.27 (1.04-1.55) 1.15 (0.94-1.40) 
      
<34 weeks      
Tested during pregnancy negative  18577 257 1.00 1.00 
 positive  1246 19 0.83 (0.52-1.34) 0.68 (0.42-1.09) 
      
Tested prior to pregnancy negative  16417 204 1.00 1.00 
 positive  1475 29 1.40 (0.94-2.08) 1.17 (0.78-1.74) 
      
Combined tested during and prior to pregnancy 
 
negative  34994 461 1.00 1.00 
 positive  2721 48 1.12 (0.83-1.51) 0.94 (0.69-1.28) 
*Adjusted for age, area of residence, and socioeconomic status  
+Adjusted for age, area of residence, socioeconomic status, smoked during pregnancy, other infections listed in table 1 and ethnicity 
 
 
